A Ashkenazi

Summary

Affiliation: Genentech Inc
Country: USA

Publications

  1. ncbi request reprint Death receptors: signaling and modulation
    A Ashkenazi
    Department of Molecular Oncology, Genentech Inc, 1 DNA Way, South San Francisco, CA 94080, USA
    Science 281:1305-8. 1998
  2. ncbi request reprint Elimination of hepatic metastases of colon cancer cells via p53-independent cross-talk between irinotecan and Apo2 ligand/TRAIL
    Rajani Ravi
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Cancer Res 64:9105-14. 2004
  3. ncbi request reprint Selective knockdown of the long variant of cellular FLICE inhibitory protein augments death receptor-mediated caspase-8 activation and apoptosis
    Darcie A Sharp
    Department of Molecular Oncology, Genentech, Inc, South San Francisco, California 94080, USA
    J Biol Chem 280:19401-9. 2005
  4. ncbi request reprint Molecular determinants of kinase pathway activation by Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand
    Eugene Varfolomeev
    Department of Molecular Oncology, Genentech, Inc, South San Francisco, California 94080, USA
    J Biol Chem 280:40599-608. 2005
  5. pmc Secreted sulfatases Sulf1 and Sulf2 have overlapping yet essential roles in mouse neonatal survival
    Charles R Holst
    Department of Molecular Oncology, Genentech, Inc, South San Francisco, California, United States of America
    PLoS ONE 2:e575. 2007
  6. pmc Host genetic background impacts modulation of the TLR4 pathway by RON in tissue-associated macrophages
    Amitabha Chaudhuri
    Department of Molecular Oncology, Genentech Inc, South San Francisco, CA 94080, USA
    Immunol Cell Biol 91:451-60. 2013
  7. pmc Fcγ receptors enable anticancer action of proapoptotic and immune-modulatory antibodies
    Jeong M Kim
    Department of Cancer Immunotherapy and Hematology, Genentech Inc, South San Francisco, CA 94080, USA
    J Exp Med 210:1647-51. 2013
  8. ncbi request reprint Targeting the extrinsic apoptosis pathway in cancer
    Avi Ashkenazi
    Department of Molecular Oncology, Genentech Inc, 1 DNA Way, South San Francisco, CA 94080 4990, United States
    Cytokine Growth Factor Rev 19:325-31. 2008
  9. ncbi request reprint Targeting death and decoy receptors of the tumour-necrosis factor superfamily
    Avi Ashkenazi
    Department of Molecular Oncology, Genentech, Inc, 1 DNA Way, South San Francisco, California 94080, USA
    Nat Rev Cancer 2:420-30. 2002
  10. pmc To kill a tumor cell: the potential of proapoptotic receptor agonists
    Avi Ashkenazi
    Genentech, South San Francisco, California 94080, USA
    J Clin Invest 118:1979-90. 2008

Collaborators

Detail Information

Publications67

  1. ncbi request reprint Death receptors: signaling and modulation
    A Ashkenazi
    Department of Molecular Oncology, Genentech Inc, 1 DNA Way, South San Francisco, CA 94080, USA
    Science 281:1305-8. 1998
    ..Certain cells have unique sensors, termed death receptors, on their surface. Death receptors detect the presence of extracellular death signals and, in response, they rapidly ignite the cell's intrinsic apoptosis machinery...
  2. ncbi request reprint Elimination of hepatic metastases of colon cancer cells via p53-independent cross-talk between irinotecan and Apo2 ligand/TRAIL
    Rajani Ravi
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Cancer Res 64:9105-14. 2004
    ....
  3. ncbi request reprint Selective knockdown of the long variant of cellular FLICE inhibitory protein augments death receptor-mediated caspase-8 activation and apoptosis
    Darcie A Sharp
    Department of Molecular Oncology, Genentech, Inc, South San Francisco, California 94080, USA
    J Biol Chem 280:19401-9. 2005
    ..Thus, endogenous c-FLIP(L) functions primarily as an inhibitor of death receptor-mediated apoptosis...
  4. ncbi request reprint Molecular determinants of kinase pathway activation by Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand
    Eugene Varfolomeev
    Department of Molecular Oncology, Genentech, Inc, South San Francisco, California 94080, USA
    J Biol Chem 280:40599-608. 2005
    ..One function of kinase stimulation by Apo2L/TRAIL may be to promote phagocytic engulfment of apoptotic cells...
  5. pmc Secreted sulfatases Sulf1 and Sulf2 have overlapping yet essential roles in mouse neonatal survival
    Charles R Holst
    Department of Molecular Oncology, Genentech, Inc, South San Francisco, California, United States of America
    PLoS ONE 2:e575. 2007
    ..The roles of Sulf1 and Sulf2 during normal development are not well understood...
  6. pmc Host genetic background impacts modulation of the TLR4 pathway by RON in tissue-associated macrophages
    Amitabha Chaudhuri
    Department of Molecular Oncology, Genentech Inc, South San Francisco, CA 94080, USA
    Immunol Cell Biol 91:451-60. 2013
    ..These findings provide novel insight into the complex interplay between genetic context and immune function. ..
  7. pmc Fcγ receptors enable anticancer action of proapoptotic and immune-modulatory antibodies
    Jeong M Kim
    Department of Cancer Immunotherapy and Hematology, Genentech Inc, South San Francisco, CA 94080, USA
    J Exp Med 210:1647-51. 2013
    ..Here, we outline a conceptual framework for understanding these findings and discuss their mechanistic and translational implications. ..
  8. ncbi request reprint Targeting the extrinsic apoptosis pathway in cancer
    Avi Ashkenazi
    Department of Molecular Oncology, Genentech Inc, 1 DNA Way, South San Francisco, CA 94080 4990, United States
    Cytokine Growth Factor Rev 19:325-31. 2008
    ..Initial data on rhApo2L/TRAIL and Apomab from phase 1 safety trials also confirm that these agents are suitable for further clinical investigation...
  9. ncbi request reprint Targeting death and decoy receptors of the tumour-necrosis factor superfamily
    Avi Ashkenazi
    Department of Molecular Oncology, Genentech, Inc, 1 DNA Way, South San Francisco, California 94080, USA
    Nat Rev Cancer 2:420-30. 2002
  10. pmc To kill a tumor cell: the potential of proapoptotic receptor agonists
    Avi Ashkenazi
    Genentech, South San Francisco, California 94080, USA
    J Clin Invest 118:1979-90. 2008
    ..Novel molecular biomarkers may help identify those patients most likely to benefit from PARA therapy...
  11. doi request reprint Directing cancer cells to self-destruct with pro-apoptotic receptor agonists
    Avi Ashkenazi
    Department of Molecular Oncology, Genentech Inc, 1 DNA Way, South San Francisco, California 94080 4918, USA
    Nat Rev Drug Discov 7:1001-12. 2008
    ..Acting alone, or in concert with other agents, PARAs may overcome key apoptosis blocks and direct cancer cells to self-destruct...
  12. ncbi request reprint Immunoadhesins as research tools and therapeutic agents
    A Ashkenazi
    Department of Molecular Oncology, Genentech Incorporated, South San Francisco, CA 94080, USA
    Curr Opin Immunol 9:195-200. 1997
    ..Recent studies suggest that immunoadhesins also may be useful therapeutically, as inhibitors of autoimmune and inflammatory diseases...
  13. ncbi request reprint A novel receptor for Apo2L/TRAIL contains a truncated death domain
    S A Marsters
    Department of Molecular Oncology, Genentech Inc, 1 DNA Way, South San Francisco, California 94080 4918, USA
    Curr Biol 7:1003-6. 1997
    ..Upon overexpression, DcR2 did not activate apoptosis or nuclear factor-kappaB; however, it substantially reduced cellular sensitivity to Apo2L-induced apoptosis. These results suggest that DcR2 functions as an inhibitory Apo2L receptor...
  14. ncbi request reprint Isotype-dependent inhibition of tumor growth in vivo by monoclonal antibodies to death receptor 4
    A Chuntharapai
    Department of Antibody Technology, Genentech, South San Francisco, CA 94080, USA
    J Immunol 166:4891-8. 2001
    ..Anti-DR4 mAbs of the IgG1 isotype may provide a useful tool for investigating the therapeutic potential of death receptor targeting in cancer...
  15. ncbi request reprint Interaction of the TNF homologues BLyS and APRIL with the TNF receptor homologues BCMA and TACI
    S A Marsters
    Departments of Molecular Oncology, Genentech, Inc, South San Francisco, CA 94080 4918, USA
    Curr Biol 10:785-8. 2000
    ..These results define a dual ligand-receptor system that may play an important role in humoral immunity...
  16. ncbi request reprint Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer
    R M Pitti
    Department of Molecular Oncology, Molecular Biology, and Immunology, Genentech, Inc, South San Francisco, California 94080, USA
    Nature 396:699-703. 1998
    ..Thus, certain tumours may escape FasL-dependent immune-cytotoxic attack by expressing a decoy receptor that blocks FasL...
  17. ncbi request reprint A unique zinc-binding site revealed by a high-resolution X-ray structure of homotrimeric Apo2L/TRAIL
    S G Hymowitz
    Department of Protein Engineering, Genentech, Inc, 1 DNA Way, South San Francisco, California 94080, USA
    Biochemistry 39:633-40. 2000
    ..The zinc ion is required for maintaining the native structure and stability and, hence, the biological activity of Apo2L. This is the first example of metal-dependent oligomerization and function of a cytokine...
  18. ncbi request reprint Activation of apoptosis by Apo-2 ligand is independent of FADD but blocked by CrmA
    S A Marsters
    Department of Molecular Oncology, Genantech Inc, South San Francisco, California 94080, USA
    Curr Biol 6:750-2. 1996
    ..These results suggest that Apo-2L activates a rapid, FADD-independent pathway to trigger a cell-death programme that requires the function of cysteine proteases such as ICE or CPP32/Yama...
  19. ncbi request reprint TACI-ligand interactions are required for T cell activation and collagen-induced arthritis in mice
    H Wang
    Department of Immunology, Genentech Inc South San Francisco, CA 94080, USA
    Nat Immunol 2:632-7. 2001
    ..Inhibition of these ligands might have therapeutic benefits for autoimmune diseases, such as RA, that involve both B and T cells...
  20. ncbi request reprint Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors
    J P Sheridan
    Department of Molecular Oncology, Genentech, South San Francisco, CA 94080 4918, USA
    Science 277:818-21. 1997
    ..DcR1 acted as a decoy receptor that inhibited TRAIL signaling. Thus, a cell surface mechanism exists for the regulation of cellular responsiveness to pro-apoptotic stimuli...
  21. ncbi request reprint A humanized, bispecific immunoadhesin-antibody that retargets CD3+ effectors to kill HIV-1-infected cells
    S M Chamow
    Department of Recovery Sciences, Genentech Inc, South San Francisco, CA 94080
    J Immunol 153:4268-80. 1994
    ..The unimpaired cytocidal activity of the BIA in the presence of serum highlights a potentially important advantage of this type of construct over native Abs for HIV-directed therapy...
  22. doi request reprint Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5
    C Adams
    Department of Antibody Engineering, Genentech Inc, South San Francisco, CA 94080 4918, USA
    Cell Death Differ 15:751-61. 2008
    ..These results provide structural and functional insight into the interaction of Apomab with DR5 and support further investigation of this antibody for cancer therapy...
  23. ncbi request reprint Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with death receptor 5
    S G Hymowitz
    Department of Protein Engineering, Genentech, Inc, South San Francisco, California 94080, USA
    Mol Cell 4:563-71. 1999
    ..A comparison to the structure of the lymphotoxin-receptor complex suggests general principles of binding and specificity for ligand recognition in the TNF receptor superfamily...
  24. ncbi request reprint Apo-3, a new member of the tumor necrosis factor receptor family, contains a death domain and activates apoptosis and NF-kappa B
    S A Marsters
    Department of Molecular Oncology, Genentech, Inc, South San Francisco, California 94080 4918, USA
    Curr Biol 6:1669-76. 1996
    ..The death domain of TNFR1 mediates the activation of programmed cell death (apoptosis) and of the transcription factor NF-kappa B, whereas the death domain of CD95 only appears to activate apoptosis...
  25. pmc Mapping the CD4 binding site for human immunodeficiency virus by alanine-scanning mutagenesis
    A Ashkenazi
    Department of Molecular Biology, Genentech, South San Francisco, CA 94080
    Proc Natl Acad Sci U S A 87:7150-4. 1990
    ..7- to 2-fold individually and 4.2-fold when combined), suggesting that it may be possible to improve the HIV-blocking ability of CD4-based molecules by increasing their gp120 binding affinity...
  26. ncbi request reprint Delineation of the cell-extrinsic apoptosis pathway in the zebrafish
    P M Eimon
    Department of Molecular Oncology, Genentech Inc, 1 DNA Way, South San Francisco, CA 94080, USA
    Cell Death Differ 13:1619-30. 2006
    ....
  27. ncbi request reprint Identification of a ligand for the death-domain-containing receptor Apo3
    S A Marsters
    Department of Molecular Oncology Genentech Inc 1 DNA Way, South San Francisco, California, 94080 4918, USA
    Curr Biol 8:525-8. 1998
    ..Thus, Apo3L has overlapping signaling functions with TNF, but displays a much wider tissue distribution...
  28. ncbi request reprint Modification of CD4 immunoadhesin with monomethoxypoly(ethylene glycol) aldehyde via reductive alkylation
    S M Chamow
    Department of Process Science, Genentech, Inc, South San Francisco, California 94080
    Bioconjug Chem 5:133-40. 1994
    ..Such modification can lead to a significant additional increase in the in vivo residence time of the protein...
  29. ncbi request reprint Cooperation of the proapoptotic receptor agonist rhApo2L/TRAIL with the CD20 antibody rituximab against non-Hodgkin lymphoma xenografts
    Dylan Daniel
    Department of Molecular Oncology, Genentech, South San Francisco, CA 94080, USA
    Blood 110:4037-46. 2007
    ..These findings provide a strong rationale for clinical investigation of rhApo2L/TRAIL in combination with rituximab as a novel strategy for NHL therapy...
  30. ncbi request reprint Identification of a receptor for BLyS demonstrates a crucial role in humoral immunity
    M Yan
    Department of Molecular Oncology, Genentech, Inc, 1 DNA Way, South San Francisco, CA 94080, USA
    Nat Immunol 1:37-41. 2000
    ..Thus, BLyS activity must play a critical role in the humoral immune response...
  31. ncbi request reprint Determination of residues involved in ligand binding and signal transmission in the human IFN-alpha receptor 2
    A Chuntharapai
    Department of Antibody Technology, Genentech Inc, South San Francisco, CA 94080, USA
    J Immunol 163:766-73. 1999
    ..In summary, we have identified specific residues of hIFNAR2 important for the binding to hIFN-alpha2/1 and demonstrate that specific regions of the IFNAR interact with the subspecies of type I IFN in different manners...
  32. ncbi request reprint Tumor-cell resistance to death receptor--induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax
    Heidi LeBlanc
    Department of Molecular Oncology, Genentech, South San Francisco, California, USA
    Nat Med 8:274-81. 2002
    ..Thus, Bax mutation in mismatch repair--deficient tumors can cause resistance to death receptor--targeted therapy, but pre-exposure to chemotherapy rescues tumor sensitivity...
  33. ncbi request reprint Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family
    R M Pitti
    Department of Molecular Oncology, Genentech, Inc, South San Francisco, California 94080 4990, USA
    J Biol Chem 271:12687-90. 1996
    ..These results suggest that, along with other family members such as Fas/Apo-1 ligand and TNF, Apo-2L may serve as an extracellular signal that triggers programmed cell death...
  34. ncbi request reprint Death receptor recruitment of endogenous caspase-10 and apoptosis initiation in the absence of caspase-8
    F C Kischkel
    Department of Molecular Oncology, Genentech, Inc, South San Francisco, California 94080, USA
    J Biol Chem 276:46639-46. 2001
    ..Thus, apoptosis signaling by death receptors involves not only caspase-8 but also caspase-10, and both caspases may have equally important roles in apoptosis initiation...
  35. ncbi request reprint Immunoadhesins: principles and applications
    S M Chamow
    Department of Recovery Sciences, Genentech, South San Francisco, CA 94080 4990, USA
    Trends Biotechnol 14:52-60. 1996
    ..In addition, we highlight some unique advantages of immunoadhesins as experimental tools in biology, as well as some of their exciting potential applications in medicine...
  36. doi request reprint Antixenograft tumor activity of a humanized anti-insulin-like growth factor-I receptor monoclonal antibody is associated with decreased AKT activation and glucose uptake
    Yonglei Shang
    Genentech, Inc, South San Francisco, California, USA
    Mol Cancer Ther 7:2599-608. 2008
    ....
  37. ncbi request reprint Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand cooperates with chemotherapy to inhibit orthotopic lung tumor growth and improve survival
    Hongkui Jin
    Department of Molecular Oncology, Genentech Inc, 1 DNA Way, South San Francisco, CA 94080, USA
    Cancer Res 64:4900-5. 2004
    ..035). These studies provide evidence for in vivo activity of Apo2L/TRAIL against lung tumor xenografts and underscore the potential of this ligand for advancing current lung cancer treatment strategies...
  38. ncbi request reprint Herpesvirus entry mediator, a member of the tumor necrosis factor receptor (TNFR) family, interacts with members of the TNFR-associated factor family and activates the transcription factors NF-kappaB and AP-1
    S A Marsters
    Department of Molecular Oncology, Genentech, Inc, South San Francisco, California 94080 4918, USA
    J Biol Chem 272:14029-32. 1997
    ..These results suggest that HVEM is linked via TRAFs to signal transduction pathways that activate the immune response...
  39. ncbi request reprint Targeting FGF19 inhibits tumor growth in colon cancer xenograft and FGF19 transgenic hepatocellular carcinoma models
    L R Desnoyers
    1Department of Molecular Oncology, Genentech Inc, South San Francisco, CA, USA
    Oncogene 27:85-97. 2008
    ..These findings suggest that the inactivation of FGF19 could be beneficial for the treatment of colon cancer, liver cancer and other malignancies involving interaction of FGF19 and FGFR4...
  40. ncbi request reprint Apo2L/TRAIL and its death and decoy receptors
    H N LeBlanc
    Department of Molecular Oncology, Genetech, Inc, South San Francisco, CA 94080, USA
    Cell Death Differ 10:66-75. 2003
    ..In this review, we focus on the apoptotic signalling pathways stimulated by Apo2L/TRAIL and summarise what is known about its physiological role...
  41. doi request reprint Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/Tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL)
    Avi Ashkenazi
    Department of Molecular Oncology, Genentech Inc, South San Francisco, CA 94080, USA
    J Clin Oncol 26:3621-30. 2008
    ..Clinical studies are ongoing to assess the safety and efficacy of this novel agent in combination with established anticancer therapies...
  42. pmc Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice
    Jing Qing
    Department of Molecular Oncology, Genentech Inc, South San Francisco, California, USA
    J Clin Invest 119:1216-29. 2009
    ..These studies provide in vivo evidence demonstrating an oncogenic role of FGFR3 in bladder cancer and support antibody-based targeting of FGFR3 in hematologic and epithelial cancers driven by WT or mutant FGFR3...
  43. ncbi request reprint Cooperation of the agonistic DR5 antibody apomab with chemotherapy to inhibit orthotopic lung tumor growth and improve survival
    Hongkui Jin
    Department of Translational Oncology, Genentech, Inc, South San Francisco, California 94080, USA
    Clin Cancer Res 14:7733-40. 2008
    ..Several lung cancer cell lines express DR5 and exhibit apoptosis in response to apomab in vitro...
  44. ncbi request reprint Targeting death receptors in cancer with Apo2L/TRAIL
    Sean K Kelley
    Genentech Inc, 1 DNA Way, South San Francisco, California 94080, USA
    Curr Opin Pharmacol 4:333-9. 2004
    ..Thus, Apo2L/TRAIL might be effective against tumors that have acquired resistance to conventional therapy, and could augment the efficacy of current treatment in a wide spectrum of cancers...
  45. ncbi request reprint Receptor-selective mutants of apoptosis-inducing ligand 2/tumor necrosis factor-related apoptosis-inducing ligand reveal a greater contribution of death receptor (DR) 5 than DR4 to apoptosis signaling
    Robert F Kelley
    Department of Protein Engineering, Genentech, Inc, South San Francisco, California 94080, USA
    J Biol Chem 280:2205-12. 2005
    ..These results suggest that DR5 may contribute more than DR4 to Apo2L/TRAIL-induced apoptosis in cancer cells that express both death receptors...
  46. ncbi request reprint Acetylcholine analogue stimulates DNA synthesis in brain-derived cells via specific muscarinic receptor subtypes
    A Ashkenazi
    Department of Molecular Biology, Genentech, Incorporated, South San Francisco, California 94080
    Nature 340:146-50. 1989
    ....
  47. pmc X chromosome-linked inhibitor of apoptosis regulates cell death induction by proapoptotic receptor agonists
    Eugene Varfolomeev
    Department of Protein Engineering, Genentech, Inc, South San Francisco, California 94080, USA
    J Biol Chem 284:34553-60. 2009
    ....
  48. doi request reprint Development of immunohistochemistry assays to assess GALNT14 and FUT3/6 in clinical trials of dulanermin and drozitumab
    Howard M Stern
    Departments of Research Pathology, Development Oncology Diagnostics, and Molecular Oncology, Genentech, Inc, South San Francisco, California, USA
    Clin Cancer Res 16:1587-96. 2010
    ....
  49. pmc Interferon gamma signals via a high-affinity multisubunit receptor complex that contains two types of polypeptide chain
    S A Marsters
    Department of Molecular Biology, Genentech, Inc, South San Francisco, CA 94080, USA
    Proc Natl Acad Sci U S A 92:5401-5. 1995
    ....
  50. ncbi request reprint Enzymatic cleavage of a CD4 immunoadhesin generates crystallizable, biologically active Fd-like fragments
    S M Chamow
    Department of Recovery Process Research and Development, Genentech, Inc, South San Francisco, California 94080
    Biochemistry 29:9885-91. 1990
    ..abstract truncated at 250 words)..
  51. pmc Death-receptor activation halts clathrin-dependent endocytosis
    Cary D Austin
    Department of Research Administration, Genentech, Inc, South San Francisco, CA 94080, USA
    Proc Natl Acad Sci U S A 103:10283-8. 2006
    ..Thus, DR-triggered caspase activity disrupts clathrin-dependent endocytosis, leading to amplification of programmed cell death...
  52. doi request reprint Cullin3-based polyubiquitination and p62-dependent aggregation of caspase-8 mediate extrinsic apoptosis signaling
    Zhaoyu Jin
    Department of Molecular Oncology, Genentech, Inc, 1 DNA Way, South San Francisco, CA 94080, USA
    Cell 137:721-35. 2009
    ..These results identify a mechanism that positively controls apoptosis signaling by polyubiquitination and aggregation of a key initiator caspase...
  53. ncbi request reprint Activation of the proapoptotic death receptor DR5 by oligomeric peptide and antibody agonists
    Bing Li
    Department of Protein Engineering, Genentech Inc, 1 DNA Way, South San Francisco, CA 94080, USA
    J Mol Biol 361:522-36. 2006
    ..These phage-derived ligands may be useful for elucidating DR5 activation at the molecular level and for creating synthetic agonists of proapoptotic death receptors...
  54. doi request reprint New insights into apoptosis signaling by Apo2L/TRAIL
    F Gonzalvez
    Department of Molecular Oncology, Genentech Inc, South San Francisco, CA, USA
    Oncogene 29:4752-65. 2010
    ..Herein, we review key advances in understanding the molecular events that control apoptosis signaling by Apo2L/TRAIL, which may aid in the development of cancer therapies based on the extrinsic apoptotic pathway...
  55. ncbi request reprint Cloning and expression of a human CDC42 GTPase-activating protein reveals a functional SH3-binding domain
    E T Barfod
    Department of Molecular Biology, Genentech, Inc, South San Francisco, California 94080
    J Biol Chem 268:26059-62. 1993
    ..Binding experiments show that this motif can interact with the SH3 domains of p85 alpha and of c-Src. Thus, CDC42GAP may function as a link between CDC42 and other signaling pathways...
  56. ncbi request reprint Functional characterization of the Bcl-2 gene family in the zebrafish
    E Kratz
    Department of Molecular Oncology, Genentech Inc, South San Francisco, CA 94080, USA
    Cell Death Differ 13:1631-40. 2006
    ..These data indicate substantial functional similarity between zebrafish and mammalian Bcl-2 family members, and establish the zebrafish as a relevant model for studying the intrinsic apoptosis pathway...
  57. ncbi request reprint Design, construction, and in vitro analyses of multivalent antibodies
    Kathy Miller
    Department of Immunology, Genentech, Inc, South San Francisco, CA 94080, USA
    J Immunol 170:4854-61. 2003
    ....
  58. doi request reprint Death receptor signal transducers: nodes of coordination in immune signaling networks
    Nicholas S Wilson
    Genentech, Inc, South San Francisco, California, USA
    Nat Immunol 10:348-55. 2009
    ..Thus, DR signal transducers may provide important nodes of coordination in immune signaling networks...
  59. ncbi request reprint TWEAK attenuates the transition from innate to adaptive immunity
    Heather Maecker
    Department of Molecular Oncology, Genentech, Inc, 1 DNA Way, South San Francisco, CA 94080, USA
    Cell 123:931-44. 2005
    ..Thus, TWEAK suppresses production of IFN-gamma and IL-12, curtailing the innate response and its transition to adaptive TH1 immunity...
  60. ncbi request reprint Tumor necrosis factor: an apoptosis JuNKie?
    Eugene E Varfolomeev
    Genentech, Inc, 1 DNA Way, South San Francisco, CA 94080, USA
    Cell 116:491-7. 2004
    ..Here, we review recent data on the role of JNK in the regulation of TNF-dependent apoptosis and discuss what is known so far about how cells decide whether to live or die in response to TNF...
  61. pmc APRIL-deficient mice have normal immune system development
    Eugene Varfolomeev
    Department of Molecular Oncology, Genentech Inc, South San Francisco, California 94080, USA
    Mol Cell Biol 24:997-1006. 2004
    ..These data indicate that APRIL is dispensable in the mouse for proper development. Thus, BLyS may be capable of fulfilling APRIL's main functions...
  62. ncbi request reprint Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL
    Klaus W Wagner
    Department of Molecular Diagnostics, Genentech, Inc, 1 DNA Way, South San Francisco, California 94080, USA
    Nat Med 13:1070-7. 2007
    ..These results uncover a new link between death-receptor O-glycosylation and apoptotic signaling, providing potential predictive biomarkers for Apo2L/TRAIL-based cancer therapy...
  63. pmc Resistance of primary isolates of human immunodeficiency virus type 1 to soluble CD4 is independent of CD4-rgp120 binding affinity
    A Ashkenazi
    Department of Immunobiology, Genentech, Inc, South San Francisco, CA 94080
    Proc Natl Acad Sci U S A 88:7056-60. 1991
    ..These results suggest that the lower sensitivity of primary HIV-1 isolates to neutralization by CD4-based molecules is not due to lower binding affinity between soluble CD4 and free gp120...
  64. ncbi request reprint Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy
    Alexandru Almasan
    Department of Cancer Biology, Lerner Research Institute, The Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Cytokine Growth Factor Rev 14:337-48. 2003
    ..In this review, we focus on the apoptosis signaling pathways stimulated by Apo2L/TRAIL, summarize what is known to date about the physiological role of this ligand and the potential for its application to cancer therapy...
  65. pmc Regulation of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in thyroid carcinoma cells
    Vassiliki Poulaki
    Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts 02114, USA
    Am J Pathol 161:643-54. 2002
    ..T helper-1 cytokines and compounds that selectively abrogate the IGF-1 signaling pathway may be helpful adjunct agents in Apo2L/TRAIL-based anti-cancer therapeutic regimens...
  66. ncbi request reprint TNF-related apoptosis-inducing ligand (TRAIL)/Apo2L suppresses experimental autoimmune encephalomyelitis in mice
    Erika Cretney
    Cancer Immunology Program, Sir Donald and Lady Trescowthick Laboratories, Peter MacCallum Cancer Centre, Victoria, Australia
    Immunol Cell Biol 83:511-9. 2005
    ..These data are the first to illustrate the potential therapeutic value of recombinant TRAIL/Apo2L in suppressing T-cell-mediated autoimmune diseases...
  67. ncbi request reprint Toward small-molecule agonists of TNF receptors
    Sarah G Hymowitz
    Nat Chem Biol 1:353-4. 2005